BJOG : an international journal of obstetrics and gynaecology
-
Randomized Controlled Trial
Intrauterine lignocaine as an anaesthetic during endometrial sampling: a randomised double-blind controlled trial.
To evaluate the effectiveness of intrauterine lignocaine as an anaesthetic during endometrial sampling. ⋯ Transcervical instillation of lignocaine reduced pain during endometrial sampling.
-
Randomized Controlled Trial
Effect of uterotonics on intra-operative blood loss during laparoscopy-assisted vaginal hysterectomy: a randomised controlled trial.
To investigate the effectiveness of uterotonics misoprostol and oxytocin on reducing blood loss during laparoscopy-assisted vaginal hysterectomy (LAVH). ⋯ Combined rectal misoprostol and intravenous oxytocin is a feasible and effective method of reducing blood loss and operation time in LAVH.
-
To study the association between volume of hospital births per annum and birth outcome for low risk women. ⋯ In Australia, lower hospital volume is not associated with adverse outcomes for low risk women.
-
To determine the cost to the NHS resulting from multiple pregnancies arising from IVF treatment in the UK, and to compare those costs with the cost to the NHS due to singleton pregnancies resulting from IVF treatment. ⋯ Multiple pregnancies after IVF are associated with high direct costs to the NHS. Redirection of money saved by implementation of a mandatory 'two embryo transfer' policy into increased provision of IVF treatment could double the number of NHS-funded IVF treatment cycles at no extra cost. Further savings could be made if a selective 'single embryo transfer' policy were to be adopted.
-
To determine the therapeutic efficacy and safety of a nitric oxide (NO) isosorbide dinitrate donor to induce cervical ripening of women with missed abortions before surgical evacuation of the uterus. ⋯ Intracervical administration of 80 mg isosorbide dinitrate in women with missed abortions appears to be effective for cervical ripening prior to surgical evacuation of the uterus. Differences in the incidence of non-serious adverse events are not likely to be clinically significant.